Pfenex: consistently high manufacturing quality key for biosimilar success

By Dan Stanton contact

- Last updated on GMT

Image: iStock/ojogabonitoo
Image: iStock/ojogabonitoo

Related tags: Food and drug administration

Manufacturing quality is key for biosimilar success says Pfenex, as the US FDA continues to increase its regulatory oversight.

Over the last few months there have been a number of complete response letters issued by the US Food and Drug Administration (FDA) sent to drugmakers citing manufacturing deficiencies. Sanofi and Regeneron’s rheumatoid arthritis drug sarilumab​ was recently hit due to problems at a fill/finish plant in France, for example.

But according to Pfenex’s CEO Bert Liang, such regulatory activity is not unusual as – during a call to discuss his firm’s Q3 results – the FDA has been clear on its demands for high quality manufacturing.

While he said there has been a crackdown “particularly with overseas manufacturers,”​ he added the FDA has been even stauncher on the quality of biosimilar manufacturing.

“It is becoming much more apparent around the quality manufacturing and manifestations that are required in order to move these programs forward, [and] certainly within the biosimilar area this is key,”​ he told stakeholders.

“We are looking for molecular similarity. That molecular similarity has to be derived from high quality manufacturing and that high quality manufacturing has to be consistent. Within that context that’s the reason why you’re starting to see it a little bit more within the area of biosimilars.”

Liang’s comments on the Agency’s increasing vigilance echoes CDMO Catalent which last week​ told its stakeholders the FDA continued to up its game, leading to higher regulatory costs for the drugmaker.

Pfenex has six fully-owned biosimilar products in its pipeline, including a version of Roche’s eye mAb Lucentis (ranibizumab) which was being co-developed with Pfizer until the Big Biopharma terminated the project in August​.

According to Liang, discussions are at their early stages with potential new partners to further the molecule’s progress.

“Obviously it takes a fair amount of time to be able to move those kinds of discussions forward. That being the case again we’re excited that there’s interest there and we’re going to continue to try to, make these types of relationships work if that’s the best thing for the organisation.”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us

Products

View more

Webinars